title: Effects of antidepressant treatments on platelet tritiated imipramine binding in major depressive disorder.
abstract: The effects of four antidepressant treatments on platelet tritiated imipramine binding have been studied in 51 hospitalized patients with severe major depressive disorder. There was an increase in maximum binding (Bmax) during the first week of treatment with antidepressants and electroconvulsive therapy, which was further magnified after three weeks' treatment with the serotonin uptake blockers alaproclate and zimeldine hydrochloride, but the Bmax values returned to baseline levels with nortriptyline hydrochloride and electroconvulsive therapy. The equilibrium dissociation affinity constant (Kd) did not change with any of the treatments. On reexamination one or two years after admission to the study, Bmax had not reached control values in clinically recovered, drug-free patients. Low pretreatment Bmax was associated with delusions during illness and with a poor long-term clinical outcome. There was no correlation between binding parameters and monoamine metabolite concentrations in the cerebrospinal fluid, either before or during treatment.
authors.affiliation: Department of Clinical Pharmacology, Karolinska Institute, Stockholm, Sweden.
authors.forename: A
authors.initials: A
authors.lastname: Wägner
authors.forename: A
authors.initials: A
authors.lastname: Aberg-Wistedt
authors.forename: M
authors.initials: M
authors.lastname: Asberg
authors.forename: L
authors.initials: L
authors.lastname: Bertilsson
authors.forename: B
authors.initials: B
authors.lastname: Mårtensson
authors.forename: D
authors.initials: D
authors.lastname: Montero
mesh_terms: D000328:Adult; D000368:Aged; D000409:Alanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001792:Blood Platelets / Q000378:metabolism*; D002352:Carrier Proteins; D003866:Depressive Disorder / Q000097:blood / Q000523:psychology / Q000628:therapy*; D004565:Electroconvulsive Therapy; D005260:Female; D006801:Humans; D007099:Imipramine / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009661:Nortriptyline / Q000627:therapeutic use; D010043:Outcome and Process Assessment, Health Care; D011569:Psychiatric Status Rating Scales; D011955:Receptors, Drug; D017981:Receptors, Neurotransmitter / Q000187:drug effects / Q000378:metabolism; D011985:Receptors, Serotonin / Q000187:drug effects / Q000378:metabolism; D015031:Zimeldine / Q000627:therapeutic use
chemical_list: D000928:Antidepressive Agents; D002352:Carrier Proteins; D011955:Receptors, Drug; D017981:Receptors, Neurotransmitter; D011985:Receptors, Serotonin; C027775:imipramine receptor; D015031:Zimeldine; D009661:Nortriptyline; C025293:alaproclate; D000409:Alanine; D007099:Imipramine